LLY

766.13

+0.37%↑

ABBV

189.58

+0.9%↑

NVO

74.46

+2.76%↑

UNH

300.51

+0.77%↑

ABT

133.18

-0.21%↓

LLY

766.13

+0.37%↑

ABBV

189.58

+0.9%↑

NVO

74.46

+2.76%↑

UNH

300.51

+0.77%↑

ABT

133.18

-0.21%↓

LLY

766.13

+0.37%↑

ABBV

189.58

+0.9%↑

NVO

74.46

+2.76%↑

UNH

300.51

+0.77%↑

ABT

133.18

-0.21%↓

LLY

766.13

+0.37%↑

ABBV

189.58

+0.9%↑

NVO

74.46

+2.76%↑

UNH

300.51

+0.77%↑

ABT

133.18

-0.21%↓

LLY

766.13

+0.37%↑

ABBV

189.58

+0.9%↑

NVO

74.46

+2.76%↑

UNH

300.51

+0.77%↑

ABT

133.18

-0.21%↓

Search

Johnson and Johnson

Avatud

SektorTervishoid

154.49 0.84

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

153.05

Max

155.9

Põhinäitajad

By Trading Economics

Sissetulek

7.6B

11B

Müük

-627M

22B

P/E

Sektori keskmine

17.267

51.198

Aktsiakasum

2.77

Dividenditootlus

3.35

Kasumimarginaal

50.24

Töötajad

138,100

EBITDA

9.7B

16B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.98% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.35%

2.40%

Järgmine tulemuste avaldamine

16. juuli 2025

Järgmine dividendimakse kuupäev

10. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

26. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-3.3B

374B

Eelmine avamishind

153.65

Eelmine sulgemishind

154.49

Uudiste sentiment

By Acuity

36%

64%

119 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. mai 2025, 17:03 UTC

Tulu
Suurimad hinnamuutused turgudel

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

15. apr 2025, 15:12 UTC

Tulu

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15. apr 2025, 10:35 UTC

Peamised uudised
Tulu

J&J Increases Outlook After Beating 1Q Expectations

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 17:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

4. mai 2025, 04:05 UTC

Omandamised, ülevõtmised, äriostud

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

18. apr 2025, 11:00 UTC

Peamised uudised

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17. apr 2025, 20:34 UTC

Tulu

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17. apr 2025, 18:24 UTC

Tulu

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15. apr 2025, 19:06 UTC

Tulu

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15. apr 2025, 18:52 UTC

Market Talk
Tulu

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15. apr 2025, 14:54 UTC

Tulu

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. apr 2025, 13:19 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. apr 2025, 11:52 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. apr 2025, 11:14 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. apr 2025, 10:51 UTC

Tulu

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15. apr 2025, 10:37 UTC

Peamised uudised
Tulu

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson 1Q Sales $21.89B >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15. apr 2025, 10:20 UTC

Tulu

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

10.98% tõus

12 kuu keskmine prognoos

Keskmine 170.53 USD  10.98%

Kõrge 185 USD

Madal 153 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

7

Osta

8

Hoia

0

Müü

Tehniline skoor

By Trading Central

154.93 / 155.895Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

119 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.